30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Genelux Corp (GNLX)

Track

Over the last 90 days, Genelux Corp has seen significant insider selling, with a net value of -$27,681.21 and a net count of -4 executives. Total sell transactions amounted to $87,982.21, with no recorded buy transactions. Notable sales include those by President and CEO Zindrick Thomas and Chief Scientific Officer Yu Yong.
Stock chart
Ticker: GNLX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Smalling Ralph
Head of Regulatory
1 sale — total 100,000 USD
Sale 3 Jun 2026
Value US$3,554,848.07 | Price 479.25 | Shares 79,824
Planned sale 1 Jun 2026
Value US$1,971,299.67 | Price 234.98 | Shares 54,923
Proposed sale 1 Jun 2026
Value US$30,500.00 | Price 3.05 | Shares 10,000
Sale 11 May 2026
Value US$804.49 | Price 2.98 | Shares 270
Sale 11 May 2026
Value US$8,225.56 | Price 2.94 | Shares 2,798
Sale 11 May 2026
Value US$1,799.39 | Price 2.97 | Shares 605
Sale 11 May 2026
Value US$1,798.42 | Price 2.97 | Shares 605
Sale 25 Mar 2026
Value US$602.40 | Price 2.51 | Shares 240
Sale 24 Mar 2026
Value US$2,192.52 | Price 2.42 | Shares 906
Sale 24 Mar 2026
Value US$2,192.52 | Price 2.42 | Shares 906
Sale 24 Mar 2026
Value US$834.90 | Price 2.42 | Shares 345
Sale 24 Mar 2026
Value US$8,668.44 | Price 2.42 | Shares 3,582
Planned sale 2 Mar 2026
Value US$28,957.00 | Price 2.90 | Shares 10,000
Proposed sale 2 Mar 2026
Value US$29,800.00 | Price 2.98 | Shares 10,000
Sale 5 Dec 2025
Value US$773.85 | Price 4.69 | Shares 165
Planned sale 1 Dec 2025
Value US$50,008.00 | Price 5.00 | Shares 10,000
Proposed sale 1 Dec 2025
Value US$55,600.00 | Price 5.56 | Shares 10,000
Sale 17 Nov 2025
Value US$5,224.43 | Price 5.37 | Shares 973
Planned sale 17 Nov 2025
Value US$24,210.62 | Price 5.37 | Shares 4,509
Sale 17 Nov 2025
Value US$5,224.43 | Price 5.37 | Shares 973
Sale 17 Nov 2025
Value US$1,841.70 | Price 5.37 | Shares 343
Sale 3 Sep 2025
Value US$1,948.22 | Price 3.36 | Shares 580
Sale 21 Aug 2025
Value US$10,807.47 | Price 3.36 | Shares 3,219
Planned sale 21 Aug 2025
Value US$42,159.27 | Price 3.33 | Shares 12,673
Sale 21 Aug 2025
Value US$4,911.88 | Price 3.36 | Shares 1,463
Sale 21 Aug 2025
Value US$4,224.91 | Price 3.33 | Shares 1,270
Sale 21 Aug 2025
Value US$4,176.61 | Price 3.36 | Shares 1,244
Sale 12 May 2025
Value US$31,430.88 | Price 2.92 | Shares 10,764
Sale 12 May 2025
Value US$3,676.28 | Price 2.92 | Shares 1,259
Sale 12 May 2025
Value US$13,067.00 | Price 2.92 | Shares 4,475
Sale 12 May 2025
Value US$13,832.04 | Price 2.92 | Shares 4,737
Sale 12 May 2025
Value US$16,290.68 | Price 2.92 | Shares 5,579
Proposed sale 30 Dec 2024
Value US$8,511.60 | Price 2.46 | Shares 3,460
Sale 30 Dec 2024
Value US$8,511.60 | Price 2.46 | Shares 3,460
Planned sale 16 Dec 2024
Value US$4,921.02 | Price 2.34 | Shares 2,103
Planned sale 16 Dec 2024
Value US$5,873.40 | Price 2.34 | Shares 2,510
Sale 16 Dec 2024
Value US$14,742.00 | Price 2.34 | Shares 6,300
Planned sale 16 Dec 2024
Value US$33,497.10 | Price 2.34 | Shares 14,315
Sale 13 Sep 2024
Value US$84,946.13 | Price 2.57 | Shares 33,080
Sale 12 Sep 2024
Value US$86,732.14 | Price 2.73 | Shares 31,777
Planned sale 11 Sep 2024
Value US$4,498.86 | Price 2.60 | Shares 1,730
Proposed sale 11 Sep 2024
Value US$4,342.30 | Price 2.51 | Shares 1,730
Sale 11 Sep 2024
Value US$82,227.08 | Price 2.62 | Shares 31,376
Sale 10 Sep 2024
Value US$51,182.19 | Price 2.51 | Shares 20,384
Sale 9 Sep 2024
Value US$63,199.57 | Price 2.70 | Shares 23,383
Proposed sale 9 Sep 2024
Value US$392,000.00 | Price 2.80 | Shares 140,000
Sale 3 Sep 2024
Value US$89,613.79 | Price 2.09 | Shares 42,818
Sale 30 Aug 2024
Value US$309,845.90 | Price 2.17 | Shares 142,589
Sale 29 Aug 2024
Value US$211,959.80 | Price 1.98 | Shares 107,045
Sale 28 Aug 2024
Value US$32,604.84 | Price 2.05 | Shares 15,918
Sale 27 Aug 2024
Value US$108,861.86 | Price 2.11 | Shares 51,630
Sale 23 Aug 2024
Value US$91,416.00 | Price 2.29 | Shares 40,000
Proposed sale 23 Aug 2024
Value US$872,000.00 | Price 2.18 | Shares 400,000
Sale 24 Jun 2024
Value US$14,519.88 | Price 2.12 | Shares 6,849
Sale 24 Jun 2024
Value US$10,517.32 | Price 2.12 | Shares 4,961
Planned sale 24 Jun 2024
Value US$11,651.52 | Price 2.12 | Shares 5,496
Sale 15 May 2024
Value US$62,623.87 | Price 3.66 | Shares 17,094
Sale 14 May 2024
Value US$55,274.44 | Price 3.58 | Shares 15,426
Sale 13 May 2024
Value US$12,478.31 | Price 3.62 | Shares 3,446
Sale 8 May 2024
Value US$53,188.67 | Price 3.82 | Shares 13,919
Sale 7 May 2024
Value US$22,111.15 | Price 3.67 | Shares 6,025
Sale 1 May 2024
Value US$109,160.81 | Price 3.30 | Shares 33,061
Sale 30 Apr 2024
Value US$63,980.90 | Price 3.12 | Shares 20,535
Sale 29 Apr 2024
Value US$20,792.46 | Price 3.25 | Shares 6,403
Sale 24 Apr 2024
Value US$28,250.61 | Price 3.50 | Shares 8,064
Sale 23 Apr 2024
Value US$76,799.80 | Price 3.49 | Shares 22,000
Sale 22 Apr 2024
Value US$50,597.03 | Price 3.53 | Shares 14,331
Sale 17 Apr 2024
Value US$84,424.75 | Price 3.71 | Shares 22,737
Sale 16 Apr 2024
Value US$171,802.31 | Price 3.53 | Shares 48,683
Proposed sale 15 Apr 2024
Value US$2,102,662.00 | Price 4.25 | Shares 494,744
Proposed sale 15 Apr 2024
Value US$2,102,662.00 | Price 4.25 | Shares 494,744
Sale 15 Dec 2023
Value US$82,265.07 | Price 14.18 | Shares 5,803
Sale 15 Dec 2023
Value US$345,914.75 | Price 12.94 | Shares 26,732
Proposed sale 15 Dec 2023
Value US$428,180.12 | Price 13.16 | Shares 32,535
Sale 13 Dec 2023
Value US$26,838.68 | Price 13.93 | Shares 1,927
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-04 2026-06-03 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
79,824 +11.0%
479.25
US$3,554,848 		79,824 +11.0% 479.25 US$3,554,848
2026-06-02 2026-06-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
54,923 -19.7%
234.98
US$1,971,300 		54,923 -19.7% 234.98 US$1,971,300
2026-06-01 2026-06-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
76,198
425.29
US$142,243 		76,198 425.29 US$142,243
2026-05-12 2026-05-11 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
270 -0.4%
2.98
US$804 		270 -0.4% 2.98 US$804
2026-05-12 2026-05-11 S Sale
3.0
Zindrick Thomas

President and CEO

Officer
2,798 -0.5%
2.94
US$8,226 		2,798 -0.5% 2.94 US$8,226
2026-05-12 2026-05-11 S Sale
3.3
Cappello Joseph

Chief Technical Officer

Officer
605 -0.4%
2.97
US$1,799 		605 -0.4% 2.97 US$1,799
2026-05-12 2026-05-11 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
605 -0.4%
2.97
US$1,798 		605 -0.4% 2.97 US$1,798
2026-03-26 2026-03-25 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
240 -0.4%
2.51
US$602 		240 -0.4% 2.51 US$602
2026-03-26 2026-03-24 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.3
Cappello Joseph

Chief Technical Officer

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
345 -0.5%
2.42
US$835 		345 -0.5% 2.42 US$835
2026-03-26 2026-03-24 S Sale
3.0
Zindrick Thomas

President and CEO

Officer
3,582 -0.7%
2.42
US$8,668 		3,582 -0.7% 2.42 US$8,668
2026-03-03 2026-03-02 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
2.90
US$28,957 		10,000 -2.0% 2.90 US$28,957
2026-03-02 2026-03-02 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
10,000
2.98
US$29,800 		10,000 2.98 US$29,800
2025-12-09 2025-12-05 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
165 -0.2%
4.69
US$774 		165 -0.2% 4.69 US$774
2025-12-02 2025-12-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
5.00
US$50,008 		10,000 -2.0% 5.00 US$50,008
2025-12-01 2025-12-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Director

Non-Executive Director
10,000
5.56
US$55,600 		10,000 5.56 US$55,600
2025-12-11 2025-11-17 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
973 -0.7%
5.37
US$5,224 		973 -0.7% 5.37 US$5,224
2025-12-11 2025-11-17 PlS Planned sale
3.0
Zindrick Thomas

President and CEO

Officer
4,509 -0.8%
5.37
US$24,211 		4,509 -0.8% 5.37 US$24,211
2025-12-11 2025-11-17 S Sale
3.3
Cappello Joseph

Chief Technical Officer

Officer
973 -0.6%
5.37
US$5,224 		973 -0.6% 5.37 US$5,224
2025-12-09 2025-11-17 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
343 -0.5%
5.37
US$1,842 		343 -0.5% 5.37 US$1,842
2025-12-09 2025-09-03 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
580 -0.8%
3.36
US$1,948 		580 -0.8% 3.36 US$1,948
2025-12-11 2025-08-21 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
3,219 -2.1%
3.36
US$10,807 		3,219 -2.1% 3.36 US$10,807
2025-12-11 2025-08-21 PlS Planned sale
3.0
Zindrick Thomas

President and CEO

Officer
12,673 -2.3%
3.33
US$42,159 		12,673 -2.3% 3.33 US$42,159
2025-12-11 2025-08-21 S Sale
3.3
Cappello Joseph

Chief Technical Officer

Officer
1,463 -0.9%
3.36
US$4,912 		1,463 -0.9% 3.36 US$4,912
2025-12-11 2025-08-21 S Sale
3.3
Cappello Joseph

Chief Technical Officer

Officer
1,270 -0.8%
3.33
US$4,225 		1,270 -0.8% 3.33 US$4,225
2025-12-09 2025-08-21 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
1,244 -1.8%
3.36
US$4,177 		1,244 -1.8% 3.36 US$4,177
2025-05-13 2025-05-12 S Sale
3.0
Zindrick Thomas

President and CEO

Executive Director
10,764 -5.3%
2.92
US$31,431 		10,764 -5.3% 2.92 US$31,431
2025-05-13 2025-05-12 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
1,259 -3.5%
2.92
US$3,676 		1,259 -3.5% 2.92 US$3,676
2025-05-13 2025-05-12 S Sale
2.6
Ryder Sean

General Counsel

Officer
4,475 -8.6%
2.92
US$13,067 		4,475 -8.6% 2.92 US$13,067
2025-05-13 2025-05-12 S Sale
3.3
Cappello Joseph

VP, Pharmaceutical Development

Officer
4,737 -8.3%
2.92
US$13,832 		4,737 -8.3% 2.92 US$13,832
2025-05-13 2025-05-12 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
5,579 -10.5%
2.92
US$16,291 		5,579 -10.5% 2.92 US$16,291
2024-12-30 2024-12-30 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
3,460
2.46
US$8,512 		3,460 2.46 US$8,512
2024-12-30 2024-12-30 S Sale
3.3
Tyree James L
Non-Executive Director
3,460 -7.0%
2.46
US$8,512 		3,460 -7.0% 2.46 US$8,512
2024-12-18 2024-12-16 PlS Planned sale
Zak Lourie S.

Chief Financial Officer

Officer
2,103 -4.9%
2.34
US$4,921 		2,103 -4.9% 2.34 US$4,921
2024-12-18 2024-12-16 PlS Planned sale
3.3
Smalling Ralph

Head of Regulatory

Officer
2,510 -13.3%
2.34
US$5,873 		2,510 -13.3% 2.34 US$5,873
2024-12-18 2024-12-16 S Sale
3.3
Cappello Joseph

VP, Pharmaceutical Development

Officer
6,300 -30.1%
2.34
US$14,742 		6,300 -30.1% 2.34 US$14,742
2024-12-18 2024-12-16 PlS Planned sale
3.0
Zindrick Thomas

President and CEO

Executive Director
14,315 -27.7%
2.34
US$33,497 		14,315 -27.7% 2.34 US$33,497
2024-09-13 2024-09-13 S Sale
4.1
Szalay Aladar
Large shareholder
33,080 -5.2%
2.57
US$84,946 		33,080 -5.2% 2.57 US$84,946
2024-09-13 2024-09-12 S Sale
4.1
Szalay Aladar
Large shareholder
31,777 -4.8%
2.73
US$86,732 		31,777 -4.8% 2.73 US$86,732
2024-09-12 2024-09-11 PlS Planned sale
3.3
Tyree James L
Non-Executive Director
1,730 -3.5%
2.60
US$4,499 		1,730 -3.5% 2.60 US$4,499
2024-09-11 2024-09-11 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
1,730
2.51
US$4,342 		1,730 2.51 US$4,342
2024-09-11 2024-09-11 S Sale
4.1
Szalay Aladar
Large shareholder
31,376 -4.5%
2.62
US$82,227 		31,376 -4.5% 2.62 US$82,227
2024-09-11 2024-09-10 S Sale
4.1
Szalay Aladar
Large shareholder
20,384 -2.8%
2.51
US$51,182 		20,384 -2.8% 2.51 US$51,182
2024-09-11 2024-09-09 S Sale
4.1
Szalay Aladar
Large shareholder
23,383 -3.2%
2.70
US$63,200 		23,383 -3.2% 2.70 US$63,200
2024-09-06 2024-09-09 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
140,000
2.80
US$392,000 		140,000 2.80 US$392,000
2024-09-06 2024-09-03 S Sale
4.1
Szalay Aladar
Large shareholder
42,818 -5.5%
2.09
US$89,614 		42,818 -5.5% 2.09 US$89,614
2024-08-30 2024-08-30 S Sale
4.1
Szalay Aladar
Large shareholder
142,589 -15.4%
2.17
US$309,846 		142,589 -15.4% 2.17 US$309,846
2024-08-30 2024-08-29 S Sale
4.1
Szalay Aladar
Large shareholder
107,045 -10.4%
1.98
US$211,960 		107,045 -10.4% 1.98 US$211,960
2024-08-30 2024-08-28 S Sale
4.1
Szalay Aladar
Large shareholder
15,918 -1.5%
2.05
US$32,605 		15,918 -1.5% 2.05 US$32,605
2024-08-27 2024-08-27 S Sale
4.1
Szalay Aladar
Large shareholder
51,630 -4.7%
2.11
US$108,862 		51,630 -4.7% 2.11 US$108,862
2024-08-27 2024-08-23 S Sale
4.1
Szalay Aladar
Large shareholder
40,000 -3.5%
2.29
US$91,416 		40,000 -3.5% 2.29 US$91,416
2024-08-22 2024-08-23 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
400,000
2.18
US$872,000 		400,000 2.18 US$872,000
2024-07-08 2024-06-24 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
6,849 -38.7%
2.12
US$14,520 		6,849 -38.7% 2.12 US$14,520
2024-07-08 2024-06-24 S Sale
2.4
Jewett Caroline

Head of Quality

Officer
4,961 -23.5%
2.12
US$10,517 		4,961 -23.5% 2.12 US$10,517
2024-07-08 2024-06-24 PlS Planned sale
2.6
Ryder Sean

General Counsel

Officer
5,496 -22.1%
2.12
US$11,652 		5,496 -22.1% 2.12 US$11,652
2024-05-15 2024-05-15 S Sale
4.1
Szalay Aladar
Large shareholder
17,094 -1.5%
3.66
US$62,624 		17,094 -1.5% 3.66 US$62,624
2024-05-15 2024-05-14 S Sale
4.1
Szalay Aladar
Large shareholder
15,426 -1.3%
3.58
US$55,274 		15,426 -1.3% 3.58 US$55,274
2024-05-15 2024-05-13 S Sale
4.1
Szalay Aladar
Large shareholder
3,446 -0.3%
3.62
US$12,478 		3,446 -0.3% 3.62 US$12,478
2024-05-09 2024-05-08 S Sale
4.1
Szalay Aladar
Large shareholder
13,919 -1.2%
3.82
US$53,189 		13,919 -1.2% 3.82 US$53,189
2024-05-09 2024-05-07 S Sale
4.1
Szalay Aladar
Large shareholder
6,025 -0.5%
3.67
US$22,111 		6,025 -0.5% 3.67 US$22,111
2024-05-01 2024-05-01 S Sale
4.1
Szalay Aladar
Large shareholder
33,061 -2.7%
3.30
US$109,161 		33,061 -2.7% 3.30 US$109,161
2024-05-01 2024-04-30 S Sale
4.1
Szalay Aladar
Large shareholder
20,535 -1.6%
3.12
US$63,981 		20,535 -1.6% 3.12 US$63,981
2024-05-01 2024-04-29 S Sale
4.1
Szalay Aladar
Large shareholder
6,403 -0.5%
3.25
US$20,792 		6,403 -0.5% 3.25 US$20,792
2024-04-24 2024-04-24 S Sale
4.1
Szalay Aladar
Large shareholder
8,064 -0.6%
3.50
US$28,251 		8,064 -0.6% 3.50 US$28,251
2024-04-24 2024-04-23 S Sale
4.1
Szalay Aladar
Large shareholder
22,000 -1.7%
3.49
US$76,800 		22,000 -1.7% 3.49 US$76,800
2024-04-24 2024-04-22 S Sale
4.1
Szalay Aladar
Large shareholder
14,331 -1.1%
3.53
US$50,597 		14,331 -1.1% 3.53 US$50,597
2024-04-18 2024-04-17 S Sale
4.1
Szalay Aladar
Large shareholder
22,737 -1.7%
3.71
US$84,425 		22,737 -1.7% 3.71 US$84,425
2024-04-18 2024-04-16 S Sale
4.1
Szalay Aladar
Large shareholder
48,683 -3.5%
3.53
US$171,802 		48,683 -3.5% 3.53 US$171,802
2024-04-15 2024-04-15 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
494,744
4.25
US$2,102,662 		494,744 4.25 US$2,102,662
2024-04-11 2024-04-15 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
494,744
4.25
US$2,102,662 		494,744 4.25 US$2,102,662
2023-12-18 2023-12-15 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
5,803 -100.0%
14.18
US$82,265 		5,803 -100.0% 14.18 US$82,265
2023-12-18 2023-12-15 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
26,732 -82.2%
12.94
US$345,915 		26,732 -82.2% 12.94 US$345,915
2023-12-15 2023-12-15 PrS Proposed sale
3.8
YONG YU

Officer

Officer
32,535
13.16
US$428,180 		32,535 13.16 US$428,180
2023-12-14 2023-12-13 S Sale
3.1
Thomas John
Non-Executive Director
1,927 -0.4%
13.93
US$26,839 		1,927 -0.4% 13.93 US$26,839
Explore more

More insider trading research around Genelux Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America